mRNA
mRNA covid vaccines may boost cancer immunotherapy survival
An analysis of nearly 1,000 cancer patients shows that mRNA covid-19 vaccines, given soon after starting immune checkpoint inhibitors, nearly doubled survival times for advanced lung and skin cancers. The findings, presented at a medical congress in Berlin, suggest an unexpected immune boost from the vaccines. A clinical trial to confirm these results is set to begin before year's end.
Next-generation mRNA vaccines aim for stronger immune responses
Rapportert av AI
Scientists have developed mRNA vaccines that produce virus-like nanoparticles inside cells, potentially offering more robust immune responses than current versions. In mouse studies, this approach generated antibody levels up to 28 times higher than standard mRNA vaccines. The innovation could reduce side effects by allowing lower doses while maintaining efficacy.
COVID-19 mRNA vaccines linked to longer survival in some lung and skin cancer patients on immunotherapy
Heather Vogel Faktasjekket
A large retrospective study from the University of Florida and The University of Texas MD Anderson Cancer Center, published in Nature, reports that patients with advanced non-small cell lung cancer or metastatic melanoma lived significantly longer if they received a Pfizer-BioNTech or Moderna COVID-19 mRNA shot within 100 days of starting immune checkpoint inhibitors. The authors stress the findings are observational and will require confirmation in randomized trials.